Parallel import licences granted in 2026.
Similar Posts
MHRA Safety Roundup: July 2025
Summary of the latest safety advice for medicines and medical device users
MHRA approves adrenaline nasal spray – the first needle-free emergency treatment for anaphylaxis in the UK
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 18 July 2025, approved adrenaline (epinephrine) nasal spray (EURneffy) to be used for the emergency treatment of serious allergic reactions, known as anaphylaxis.
Submission and assessment timetables for innovative medicines applications
Guidance on the deadlines for initial and response submissions.
MHRA welcomes Professor Jacob George as he starts Chief Medical and Scientific Officer role
In this new role, Professor George will lead the Agency’s science strategy and will oversee the MHRA’s scientific, research and innovation activities.
Mirvetuximab soravtansine approved to treat adult patients who have ovarian, fallopian tube or primary peritoneal cancer
The approval is supported by a study involving 453 adults with advanced platinum-resistant cancers of the ovary, fallopian tubes and the peritoneum that were FRα positive
Medicines marketing authorisation: change of ownership
How to change the ownership from one marketing authorisation (MA) holder to another.